Tudorza Approval History

• FDA approved: Yes (First approved July 23rd, 2012)
• Brand name: Tudorza
• Generic name: aclidinium bromide
• Company: Forest Laboratories, Inc. and Almirall, S.A.
• Treatment for: COPD

Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

FDA Approval History for Tudorza

Date	Article
Jul 23, 2012	FDA Approves Tudorza Pressair to Treat Chronic Obstructive Pulmonary Disease
Feb 24, 2012	Forest and Almirall Announce Positive FDA Advisory Committee's Recommendation for Approval of Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Jun 30, 2011	Forest and Almirall Announce Submission of New Drug Application for Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

See also...

Tudorza (aclidinium bromide) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.